Long-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinoma

Simple item page
dc.contributor.authorOtaola, Hugo
dc.contributor.authorKrebs, Alfred
dc.contributor.authorBermúdez, Hugo
dc.contributor.authorLyng, Raúl
dc.contributor.authorOrvieto, Marcelo
dc.contributor.authorStein, Conrado
dc.contributor.authorLabra, Andrés
dc.contributor.authorSchultz, Marcela
dc.date.accessioned2022-08-18T16:05:45Z
dc.date.available2022-08-18T16:05:45Z
dc.date.issued2022
dc.description.abstractBackground: To evaluate long-term oncological and renal function outcomes in patients treated with robot-assisted partial nephrectomy (RAPN) for renal cell carcinoma (RCC). Patients and methods: Patients undergoing RAPN for clinically localized RCC between January 2014 and December 2019 at a tertiary robotic reference center were evaluated. Clinical course, pathologic characteristics, and long-term outcomes were obtained from our institutional review board-approved RCC database. Results: A total of 234 patients were available for analysis. Median follow-up was 46 months (10.8-97.8 months), with 77 patients (32.9%) having at least 5-years of follow-up. Pathology revealed clear-cell RCC in 67.5% (n = 158). Among unfavorable factors, nuclear grades 3 or 4 were found in 67 (29.4%), lymphovascular invasion in 10 (4.3%), positive surgical margins in 22 (9.4%), necrosis in 21 (9%), and sarcomatoid pattern in 2 patients (0.9%). At 12 months, mean serum creatinine was 1.04 mg/dL and 12.9% of patients experienced upstaging in chronic kidney disease. Overall recurrence-free survival at 5-years was 97.8%. There were five local (2.1%) and two distant (0.9%) recurrences, none of them resulting in cancer-specific death. Median time to recurrence was 20 months (11-64 months). Warm ischemia time [hazard ratio (HR) = 1.14, p = 0.034] and sarcomatoid pattern (HR = 124.57, p = 0.001) were the only variables associated with local relapse. Conclusions: Data from this large cohort demonstrate that patients undergoing RAPN have a low incidence of local and distant relapse, resulting in excellent long-term survival while preserving stable renal function in most patients.es
dc.description.versionVersión publicadaes
dc.identifier.citationOtaola-Arca H, Krebs A, Bermúdez H, Lyng R, Orvieto M, Bustamante A, Stein C, Labra A, Schultz M, Fernández MI. Long-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinoma. Ann Surg Oncol. 2022 Apr;29(4):2484-2494. doi: 10.1245/s10434-021-11133-4. Epub 2022 Jan 6. PMID: 34988833es
dc.identifier.urihttps://doi.org/10.1245/s10434-021-11133-4es
dc.identifier.urihttp://hdl.handle.net/11447/6525
dc.language.isoenes
dc.subjectCarcinoma, Renal Cell / surgeryes
dc.subjectHumanses
dc.subjectKidney Neoplasms / pathologyes
dc.subjectNephrectomy / methodses
dc.subjectNeoplasm Recurrence, Local / epidemiologyes
dc.subjectRobotics / methodses
dc.subjectTreatment Outcomees
dc.titleLong-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinomaes
dc.typeArticlees
dcterms.sourceAnnals of surgical oncologyes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Long-Term Oncological and Functional Outcomes After Robot.pdf
Size:
477.36 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services